Ceres, Inc. (California)

Oxford Bioscience Partners (OBP) focuses on investments in emerging, entrepreneurial-driven companies in the life sciences and healthcare sectors. They look for companies in the medical devices, R&D instruments and systems and therapeutics industries and for companies with breakthrough life sciences technology. The firm also invests in non-life science based technologies that have novel healthcare applications. OBP considers investments at almost any stage, but they place emphasis on early-stage opportunities. Investments range from $1 million to $10 million, but they may also make smaller seed investments in certain situations. OBP acts as the lead investor to organize an appropriate syndicate of co-investors. They consider investments in almost all geographic locations.

OppenheimerFunds, Inc. has been helping investors achieve their financial goals since 1960. We are one of the nation's largest and most respected asset management companies. At OppenheimerFunds, we believe that in order for you to reach your financial goals, your investments must perform. That is why investment excellence—over the long term and across the range of our products—is our highest priority. OppenheimerFunds and its controlled affiliates offer a broad range of products and services to individuals, corporations and institutions, including mutual funds, separately managed accounts, investment management for institutions, qualified retirement plans and subadvisory investment-management services. OppenheimerFunds is widely recognized as a leader in educating and empowering investors and for its award-winning customer service. To help us make this site of more value to you, we would appreciate your feedback. Contact us to share your thoughts or suggestions.

Gimv-PE's investment focus is typically linked to unlisted firms requiring financing to accelerate growth, for corporate divestitures, for shareholders seeking liquidity and for family-owned firms with succession issues.The firm targets investments ranging from EUR 5-30 million. They seek equity participation through majority or significant minority stakes. They provide mezzanine finance for buy-outs and growth capital. When they provide MBO financing, they create a new shareholder structure taking a majority stake alone or with other private equity partners. In terms of growth capital provision, they take minority participations essentially leaving intact the firm's existing shareholder structure.Gimv-PE's investment criteria include mid-sized firms displaying robust market position or a holding niche position. They typically invest in firms with an enterprise value between EUR 20-125 million, in a wide range of sectors and with experienced management teams having proven performance records. They look for an alignment of interest among key partners. The firm does not invest in listed firms, start-ups or turnarounds.